GO
Loading...

Sanofi SA

More

  • *European shares dip, Wall Street expected to follow. LONDON, July 7- The dollar and world shares were losing steam on Monday as the momentum from last week's strong U.S. jobs data faded and attention began to turn to the fast-approaching earnings season.

  • European shares retreat after weak German data Monday, 7 Jul 2014 | 6:28 AM ET

    *Total, Sanofi fall after cautioning over results. Some analysts said that while Europe's stock market rally could flatline in the near term, the longer-term outlook remained positive given steps taken by the European Central Bank to boost the region's economy. A fall in the shares of heavyweight stocks Total and Sanofi also pegged back European markets.

  • LONDON, July 7- The dollar was on its strongest run since late October on Monday as the momentum of last week's stellar U.S. jobs data carried markets towards what will be a crucial earnings season for record high shares.

  • European shares edge lower after German data miss Monday, 7 Jul 2014 | 4:08 AM ET

    *FTSEurofirst 300 down 0.1 pct, Euro STOXX 50 down 0.2 pct. *Total, Sanofi fall after cautioning over results. EDINBURGH, July 7- European shares fell on Monday after weak data out of Germany took the wind out of a rally that saw a top index post its best week in over three months.

  • European shares held back by weak German data Monday, 7 Jul 2014 | 3:16 AM ET

    EDINBURGH, July 7- European shares fell on Monday after weak data out of Germany took the wind out of a rally that saw a top index post its best week in over three months. German industrial output fell 1.8 percent on the month in May, its biggest drop in more than 2 years, confounding expectations of unchanged industrial output in Europe's powerhouse.

  • This drug became kosher (but it doesn't matter) Tuesday, 1 Jul 2014 | 4:08 PM ET
    Web page for Pfizer's Elelyso

    Pfizer paid a "nominal fee" to cover expenses related to the facility inspection, and to obtain a certification, a Pfizer spokeswoman said.

  • *Sanofi hit may be limited as EU market smaller than U.S. LONDON, June 27- European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015..

  • Midday movers: Alstom, CarMax, Sprint & More Friday, 20 Jun 2014 | 11:34 AM ET

    Some of Friday's midday movers:

  • Will ghoulish investments pay off? Monday, 16 Jun 2014 | 6:57 PM ET
    Elderly women wait for lunch to be served at a day care facility on Gogo Island in Matsuyama, Ehime Prefecture, Japan

    As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.

  • NEW YORK, June 16- Morgan Stanley, an adviser to Valeant Pharmaceuticals International Inc in its $53 billion hostile bid for Allergan Inc, initially tried to get hired by Allergan and in its pitch called the unsolicited bidder a "house of cards", according to Allergan.

  • PARIS, June 14- French drugmaker Sanofi said on Saturday it was teaming up with U.S. medical device maker Medtronic in diabetes. Under the terms of a memorandum of understanding, Sanofi and Medtronic will initially cooperate on developing drug-device combinations and offering care management services for diabetes patients.

  • PARIS, June 14- French drugmaker Sanofi said on Saturday it was teaming up with U.S. medical device maker Medtronic in diabetes. Under the terms of a memorandum of understanding, Sanofi and Medtronic will initially cooperate on developing drug-device combinations and offering care management services for diabetes patients.

  • Diabetes: The $54 billion battleground Friday, 13 Jun 2014 | 12:17 PM ET
    Daily implements of diabetes care.

    Many of the world's biggest drugmakers will gather starting Friday in San Francisco for the American Diabetes Association's annual meeting. Here's what investors need to know.

  • LONDON, June 13- The world's biggest would-be drugs merger hit a wall last month but speculation about smart ways that Pfizer could yet seal a deal with AstraZeneca remains intense. Even as talks fell apart last month, some in Pfizer's camp remained optimistic the transaction could be revived- and certain AstraZeneca advisers have not ruled out renewed talks.

  • BUSINESS-NEWS-SCHEDULE AT 0830 GMT / 4.30 AM ET Friday, 13 Jun 2014 | 4:50 AM ET

    LONDON- Bank of England Governor Mark Carney says that British interest rates could rise sooner than financial markets expect in a surprisingly stark warning that monetary policy may start to tighten within months. -MARKETS- UK/ REACTION, moved, by Anirban Nag, 480 words.

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • Early movers: LULU, FB, AMZN, TWTR, GS, JNJ & more Thursday, 12 Jun 2014 | 7:51 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Orexigen shares plunge on FDA diet-drug delay Wednesday, 11 Jun 2014 | 7:33 AM ET

    Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.

  • June 11- Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug by three months, sending the company's shares down about 19 percent in premarket trading.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.